The NDA was submitted for investigational muscarinic antipsychotic, KarXT (xanomeline-trospium), which functions as a dual M1/M4 muscarinic acetylcholine receptor agonist within the central nervous system.
Erin O'Brien
Advertisement
Articles by Erin O'Brien
United States leaders work together to create bipartisan solutions for the youth mental health crisis.
Risk of suicide attempt is higher among adults, women.
Survey results addressed connections between migraine and mental health, stigma, and treatment preferences.
The warnings cite consumer risks and Food, Drug and Cosmetics Act violations.
Recent research supports evidence for long-term impairment in memory, executive function.
Results highlight the impact of education on patient understanding of potential adverse events.
Catch up on all the latest in ADHD from the virtual APSARD 2022 Annual Meeting.
What are the connections between ADHD, infectious diseases, and COVID-19?
Advertisement
Latest Updated Articles
Opportunity Exists for Patient Education on Concurrent Opioid, Benzodiazepine UsePublished: March 22nd 2022 | Updated:
Spotlight: Issues in ADHDPublished: February 23rd 2022 | Updated:
NDA for Investigational Schizophrenia Treatment Submitted to FDAPublished: October 2nd 2023 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
Leading Cause of Meningitis Shifts from S. Pneumoniae to K. Pneumoniae
2
American Pharmacists Month: Technology Transforms Pharmacy Practice, Demands New Skills
3
Pharmacists Improve Diabetes Outcomes Through Continuous Glucose Monitoring Services
4
American Pharmacists Month: Evolution of Experiential Learning for Pharmacy Students
5
